RxDoctor Payments Data

David Wood, DO

Family Medicine · Tamaqua, PANPI 1447202395

Payments from drug & device makers

$1,928in general payments, 2019–2025

Across 144 payments — averaging $13.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$559
  • AstraZeneca$352
  • Novo Nordisk$226
  • Boehringer Ingelheim$150
  • Sanofi-aventis U.S. LLC$133
  • GSK$122
  • plus $387 from 10 others

What the payments were for

  • Food & beverage$1,88098%
  • Education$482%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,928 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$33,259
Medicare patients
165
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$48,694
JardianceEmpagliflozin24$25,416
XareltoRivaroxaban88$19,474
MounjaroTirzepatide12$12,597
Clomipramine Hcl35$10,965
JanuviaSitagliptin Phosphate66$10,818
Levetiracetam163$3,559
Gabapentin483$3,271
Atorvastatin Calcium400$3,237
Tamsulosin Hcl167$2,046
Furosemide402$1,750
Midodrine Hcl58$1,617
Potassium Chloride169$1,582
Levothyroxine Sodium259$1,558
Carvedilol144$1,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$48,694227 claims
Boehringer IngelheimJardiance$150$25,41624 claims
Johnson & JohnsonXarelto$64$19,47488 claims
Lilly USA, LLCMounjaro$118$12,59712 claims
MerckJanuvia$12$10,81866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Tamaqua

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →